Urogen Pharma (URGN) stock
NASDAQ
As of the Nov 13, 2026 close (U.S. Eastern)
Events and reference metrics · 1
- Market cap
- $1.28B
- As of Nov 13, 2026
- P/E
- -19.74x
- Trailing twelve months
- P/B
- Not available
- Latest reported equity
- P/S
- 5.11x
- Trailing twelve months
- ROE
- Not available
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
- Market cap
- $1.28B
- As of Nov 13, 2026
- P/E
- -19.74x
- Trailing twelve months
- P/B
- Not available
- Latest reported equity
- P/S
- 5.11x
- Trailing twelve months
- ROE
- Not available
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
-19.74x
Net loss — not comparable
P/B
—
P/S
5.11x
Earnings and dividend metrics▾
Earnings
EPS
-$1.33
Earnings per share
BPS
—
Book value per share
ROE
—
Return on equity
- EPS — what one share earned over the last four quarters. The company is currently loss-making, at $1.33 per share.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Revenue increased 229.6% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $27M+229.6%
$25M
Jul–Sep '24
$27M
Jul–Sep '25
$89M
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Nov 4, 2026.
- Revenue increased 229.6% from the same quarter a year earlier.
- Operating income increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Net income increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
Filed Nov 4, 2026 · 10-Q · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Degnan ChrisChief Financial Officer · Oct 8, 2026Open-market sale2,202 shares · $81KAvg. price $36.694,561 shares held after
- Degnan ChrisChief Financial Officer · Oct 8, 2026Option exercise4,483 shares6,763 shares held after
- Smith Jason DrewGeneral Counsel · Sep 8, 2026Open-market sale1,519 shares · $65KAvg. price $42.5453,141 shares held after
- Schoenberg MarkChief Medical Officer · Sep 8, 2026Open-market sale871 shares · $37KAvg. price $42.9259,882 shares held after
- Schoenberg MarkChief Medical Officer · Sep 7, 2026Option exercise1,667 shares60,753 shares held after
- Smith Jason DrewGeneral Counsel · Sep 7, 2026Option exercise3,334 shares54,660 shares held after
- Robinson James A. Jr.Director · Aug 26, 2026Option exercise2,000 shares8,000 shares held after
- Schoenberg MarkChief Medical Officer · Aug 20, 2026Open-market sale60,677 shares · $2.9MAvg. price $47.0559,086 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsFilings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Urogen Pharma (URGN) stock information
NASDAQ
Urogen Pharma (URGN) is listed on NASDAQ. Its market capitalization is about $1.3B. On trailing-twelve-month earnings the P/E ratio is -19.74. These figures are computed in-house from official filings and are reference information only.
Urogen Pharma — frequently asked questions
- What is the P/E ratio of Urogen Pharma (URGN)?
- On a trailing-twelve-month basis, URGN trades at a P/E ratio of -19.74. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Urogen Pharma?
- URGN has a market capitalization of about $1.3B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.